🔗 Share this article

Chancellor Reeves has revealed she is planning "focused steps to address household expense challenges" in next month's financial statement.

During an interview with media outlets, she noted that reducing price rises is a shared duty of both the administration and the central bank.

The United Kingdom's inflation rate is projected to be the most elevated among the G7 industrialized countries this year and next.

Potential Energy Bill Interventions

Sources suggest the government could take action to reduce utility costs, for example by reducing the present 5% level of value-added tax applied on energy supplies.

Another option is to lower some of the regulatory levies currently included in bills.

Fiscal Limitations and Expert Expectations

The government will obtain the latest assessment from the independent fiscal watchdog, the Office for Budget Responsibility, on the start of the week, which will clarify how much scope there is for such actions.

The consensus from most analysts is that Reeves will have to introduce tax rises or expenditure reductions in order to adhere to her voluntary borrowing rules.

Earlier on Thursday, analysis suggested there was a £22bn shortfall for the chancellor to address, which is at the lower end of expectations.

"There's a joint task between the Bank of England and the government to bear down further on some of the drivers of price increases," the Chancellor told the BBC in Washington, at the annual meetings of the International Monetary Fund and global financial institution.

Tax Commitments and Global Issues

While a great deal of the attention has been on probable tax increases, the chancellor said the most recent information from the OBR had not changed her commitment to manifesto promises not to raise tax levels on income tax, VAT or social security contributions.

She blamed an "unpredictable world" with increasing international and commercial issues for the Budget revenue measures, likely to be targeted on those "most able to pay."

Global Trade Disputes

Addressing apprehensions about the United Kingdom's economic relations with the Asian nation she said: "The UK's national security invariably are paramount."

Recent statement by China to increase export controls on critical minerals and other materials that are crucial for high-technology production led US President Donald Trump to threaten an additional 100% import tax on goods from the Asian country, raising the risk of an full-scale commercial conflict between the two economic giants.

The American finance chief described China's action "commercial pressure" and "a global supply chain control attempt."

Questioned on considering the US offer to join its dispute with the Asian nation, the Chancellor said she was "extremely troubled" by China's actions and urged the Chinese government "to avoid restrictions and limit trade."

She said the move was "bad for the global economy and causes additional obstacles."

"In my view there are areas where we should address Chinese policies, but there are also valuable opportunities to trade with Chinese markets, including financial services and other sectors of the economy. We've got to maintain that equilibrium appropriate."

The Treasury chief also stated she was working with G7 counterparts "on our own critical minerals approach, so that we are less reliant."

NHS Medicine Pricing and Investment

Reeves also acknowledged that the price the National Health Service pays for pharmaceuticals could increase as a result of ongoing talks with the Trump administration and its pharmaceutical firms, in exchange for reduced taxes and investment.

Some of the world's largest drug companies have said lately that they are either pausing or abandoning projects in the UK, with some blaming the modest returns they are receiving.

Recently, the government science advisor said the price the NHS spends on drugs would must rise to halt firms and pharmaceutical investment departing from the UK.

Reeves informed the BBC: "We have seen as a result of the cost structure, that clinical trials, new drugs have not been available in the UK in the manner that they are in other EU nations."

"The objective is to make sure that individuals getting treatment from the NHS are able to receive the finest essential treatments in the world. And so we are looking at these issues, and... looking to secure additional investment into the UK."